Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718073 | 0.85 | P2RX7 (0.35) | KCNA5KCNH2CTDSP1FAAHGOT1 | |
| SCHEMBL26538816 | 0.81 | KCNA5 (0.33) | KCNA5KCNH2CTDSP1FAAHGOT1 | |
| SCHEMBL13848610 | 0.79 | FAAH (0.34) | KCNA5KCNH2CTDSP1FAAHGOT1 | |
| SCHEMBL26666923 | 0.78 | KCNA5 (0.32) | KCNA5KCNH2CTDSP1FAAHGOT1 | |
| SCHEMBL25726630 | 0.75 | FAAH (0.35) | KCNA5KCNH2FAAH | |
| SCHEMBL23750446 | 0.73 | FAAH (0.35) | KCNA5KCNH2CTDSP1FAAH | |
| SCHEMBL26078437 | 0.73 | FAAH (0.39) | KCNH2FAAH | |
| SCHEMBL12469850 | 0.72 | GOT1 (0.34) | KCNA5KCNH2CTDSP1FAAHGOT1 | |
| SCHEMBL21661962 | 0.71 | FAAH (0.40) | KCNH2FAAH | |
| SCHEMBL22647103 | 0.71 | FAAH (0.38) | KCNH2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745002-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| EP-1745002-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105725-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | KCNA5 3745/4885KCNH2 4668/4885CTDSP1 1073/4885 |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | PPARG, PPARD, GPR119 | KCNA5 3381/4885KCNH2 4373/4885CTDSP1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.